Ocrelizumab - MS Research Australia

Ocrelizumab

Ocrelizumab

Administration Route: Infusion
Injection site:
Frequency: At the beginning of treatment, there are two doses separated by 14 days. After that, there is a single infusion every 6 months.
TGA approval date: Jul 2017, for relapsing MS
PBS listed: Yes for relapsing-remitting MS only
Mechanism of action Ocrevus is a humanised monoclonal antibody, which inhibits the growth of the CD20-positive B lymphoma cell lines, which play a major role in damaging nerve cells and the myelin sheath around the nerves.
%reduction in relapse rate, impact of progression 46% RRR in annual relapse rate, 40% RRR for new Gd lesions, 77%-83% RRR for new T2 lesions, and 40% decrease in RRR disability. These numbers are in comparison to a control group treated with IFN, previous clinical trial of earlier medications were compared to a placebo treatment group.
Pregnancy Category C
Safe in Pregnancy Avoid treatment during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment and for 6 months after the last infusion
Breastfeeding (information predominatly from  LACTMED database) Discontinue breast-feeding during therapy
Monitoring requirements
Potential side effects (not a comprehensive list) Infusion reactions and upper respiratory tract infections, which were mostly mild to moderate in severity. Potential serious side effects may include infusion reactions, infections and malignancies where only routine screening is required based on age and medical history.
Manufacturer  Roche
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search